Wesleyan chemistry teacher among Top 35 Women in Higher Education – Danbury News Times

By Wesleyan University Staff

Erika Taylor, associate professor of chemistry at Wesleyan University, is among the Top 35 Women in Higher Education in the March 20 issue of Diverse.

Erika Taylor, associate professor of chemistry at Wesleyan University, is among the Top 35 Women in Higher Education in the March 20 issue of Diverse.

Photo: Hearst Connecticut Media File Photo

Erika Taylor, associate professor of chemistry at Wesleyan University, is among the Top 35 Women in Higher Education in the March 20 issue of Diverse.

Erika Taylor, associate professor of chemistry at Wesleyan University, is among the Top 35 Women in Higher Education in the March 20 issue of Diverse.

Wesleyan chemistry teacher among Top 35 Women in Higher Education

MIDDLETOWN Erika Taylor, associate professor of chemistry at Wesleyan University, is honored among the Top 35 Women in Higher Education in the March 20 issue of Diverse Education.

Taylor joined the faculty in 2007 and teaches courses in the areas of organic chemistry, biochemistry, environmental chemistry, and bio-medicinal chemistry, among others.

Shes also associate professor, environmental studies, and associate professor, integrative sciences, and takes a multidisciplinary approach to investigating problems at the biological chemistry interface.

Diverse acknowledged Taylor for striv(ing) to find ways to exploit enzymes found in nature to perform reactions that can help advance the fields of chemistry and medicine. Her research group has included over 75 students to date, spanning high schoolers to PhD students, with women and other underrepresented students comprising more than three-quarters of her lab members.

Taylor also serves as the faculty director of Wesleyans Ronald E. McNair Post-Baccalaureate Program, which assists students from underrepresented groups in preparing for, entering, and progressing successfully through post-graduate education.

Diverse cited her for being a passionate advocate for diversity and lending time and energy to provide opportunities in science for female, minority, and low-income students.

In 2018, Taylor received Wesleyans prestigious Binswanger Prize for Excellence in Teaching for her dedication to supporting the academic and personal development of all of her students.

Beyond Wesleyan, she founded and continues to run a Girls in Science camp for elementary through middle school-aged girls, which highlights the diversity of women in science.

Taylor holds a bachelors degree in chemistry with honors from the University of Michigan at Ann Arbor, a PhD in chemistry from the University of Illinois at Urbana-Champaign, and was a postdoctoral research associate at Albert Einstein College of Medicine.

More:
Wesleyan chemistry teacher among Top 35 Women in Higher Education - Danbury News Times

What’s the Chemical Difference Between Hot- and Cold-Brew Coffee? – Popular Mechanics

Whats in your cold brew coffee, and how does it differ from a traditional hot brew?

For a new presentation poster, scientists brewed many batches to identify differences in the chemistry between cold and hot brew coffee. They confirmed ongoing study results that show hot brewed coffee has more antioxidants (and acidity) than cold brew. They also took their research a step further and examined these levels in different temperatures of roasts, from light to dark.

For their research, the scientists from Philadelphias Thomas Jefferson University had to develop the most standard possible brew. Coffee aficionados already face this question every day, and they agree that a burr grinder works best to grind beans into a uniform consistency. And many use water heaters to reach a consistent recommended temperature just below boiling.

Both of these mechanics are imperfect. Thats on top of varying levels of roast even within narrow ranges like light and medium. Coffee is one part science and one part fault-tolerant art form.

So to try to homogenize their research as much as possible, the researchers did everything they could to control the parameters. They developed a procedure for when the water should be added to the ground coffee, how to pour the water and for how long, how to shake the solution, how to press the brewed coffee and how to analyze it. They set time limits for each step, with margins of just a few seconds, the American Chemical Society (ACS) said in a statement.

What the scientists found will interest coffee lovers. Overall, pH of hot and cold brews at the same roastiness are similar, which goes against popular wisdom that cold brew coffee is less acidic than hot. (Other studies back up this finding.) The researchers observed that pH gets highermore basicas the level of roasting gets higher, so the darkest roasts have the lowest acidity.

Brewing hot coffee also results in a product with much higher antioxidant content. For lighter roast coffees, the difference is smaller, but for dark roast coffees, hot brewing extracts far more antioxidants than cold brewing. Hot brewing also has higher amounts of specific kinds of acids and dissolved solids, despite its overall similar pH.

The researchers dont speculate about this, but it could be this higher level of some acids that results in the perception that hot brew is more acidic than cold brew.

The researchers presented their poster as part of the ACSs spring national meeting. The meeting itself was canceled because of COVID-19 (coronavirus), but participants were invited to share their research presentations online. Even so, the website compiling that research is a bit of a ghost town. These researchers should be able to present their different papers and projects in a future, in-person ACS meeting.

See the rest here:
What's the Chemical Difference Between Hot- and Cold-Brew Coffee? - Popular Mechanics

A Man Attacked An Asian Woman Taking Out Her Trash At Night. She Now Has Chemical Burns On Her Face And Body. – BuzzFeed News

An Asian woman in Brooklyn, New York, was taking out her trash when a man outside her apartment building doused her with a substance that gave her chemical burns before running away, police said.

The attack took place on Sunday night in the Sunset Park neighborhood. In a video released by the New York Police Department, the woman appears to be taking out her trash when the man, who is sitting on the stoop, stands up as she exits the building, and approaches her from behind with a bottle in his hand.

"There was no interaction between the individual and the victim prior to the assault," the NYPD said.

The woman, who is 39 years old, was admitted to the Maimonides Medical Center with chemical burns to her face, neck, and back. Police said she was in stable condition.

The NYPD is asking for the public's help to identify the man, whose ethnicity is unknown. He was wearing a face mask, gloves, and a black hoodie.

Police confirmed to BuzzFeed News that the victim is Asian.

The motive behind the assault remains unclear. Reports of attacks against Asians in the US and Europe have skyrocketed in the past weeks as people express fears over the coronavirus through xenophobic and racist violence.

Law enforcement agencies in the US were also warned about a possible increase in hate crimes against Asian Americans over the coronavirus. "The FBI makes this assessment based on the assumption that a portion of the US public will associate COVID-19 with China and Asian American populations," the report stated.

President Donald Trump's rhetoric has further fueled concern that Asian communities could bear the brunt of violent backlash over the pandemic. Trump has been repeatedly condemned for choosing to refer to the coronavirus as the "Chinese virus," insisting the term is "not racist" because "it comes from China."

Though the new coronavirus originated in Wuhan, China, it quickly became a global pandemic, with the US now leading in the number of confirmed cases. The Trump administration has faced intense criticism for its inaction early in the virus's spread in the country, and for failing to provide adequate support to states battling the outbreak.

Read the original post:
A Man Attacked An Asian Woman Taking Out Her Trash At Night. She Now Has Chemical Burns On Her Face And Body. - BuzzFeed News

Should You Buy Chemical Industries (Far East) Limited (SGX:C05) For Its Dividend? – Yahoo Finance

Today we'll take a closer look at Chemical Industries (Far East) Limited (SGX:C05) from a dividend investor's perspective. Owning a strong business and reinvesting the dividends is widely seen as an attractive way of growing your wealth. Yet sometimes, investors buy a popular dividend stock because of its yield, and then lose money if the company's dividend doesn't live up to expectations.

While Chemical Industries (Far East)'s 2.4% dividend yield is not the highest, we think its lengthy payment history is quite interesting. There are a few simple ways to reduce the risks of buying Chemical Industries (Far East) for its dividend, and we'll go through these below.

Click the interactive chart for our full dividend analysis

SGX:C05 Historical Dividend Yield April 10th 2020

Companies (usually) pay dividends out of their earnings. If a company is paying more than it earns, the dividend might have to be cut. So we need to form a view on if a company's dividend is sustainable, relative to its net profit after tax. In the last year, Chemical Industries (Far East) paid out 11% of its profit as dividends. We like this low payout ratio, because it implies the dividend is well covered and leaves ample opportunity for reinvestment.

We also measure dividends paid against a company's levered free cash flow, to see if enough cash was generated to cover the dividend. Chemical Industries (Far East) paid out 55% of its free cash flow last year, which is acceptable, but is starting to limit the amount of earnings that can be reinvested into the business. It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.

While the above analysis focuses on dividends relative to a company's earnings, we do note Chemical Industries (Far East)'s strong net cash position, which will let it pay larger dividends for a time, should it choose.

Consider getting our latest analysis on Chemical Industries (Far East)'s financial position here.

From the perspective of an income investor who wants to earn dividends for many years, there is not much point buying a stock if its dividend is regularly cut or is not reliable. For the purpose of this article, we only scrutinise the last decade of Chemical Industries (Far East)'s dividend payments. Its dividend payments have declined on at least one occasion over the past ten years. Its most recent annual dividend was S$0.015 per share, effectively flat on its first payment ten years ago.

We're glad to see the dividend has risen, but with a limited rate of growth and fluctuations in the payments, we don't think this is an attractive combination.

Given that the dividend has been cut in the past, we need to check if earnings are growing and if that might lead to stronger dividends in the future. Chemical Industries (Far East)'s EPS are effectively flat over the past five years. Over the long term, steady earnings per share is a risk as the value of the dividends can be reduced by inflation. Growth has been hard to come by. On the plus side, the dividend payout ratio is low and dividends could grow faster than earnings, if the company decides to increase its payout ratio.

Story continues

When we look at a dividend stock, we need to form a judgement on whether the dividend will grow, if the company is able to maintain it in a wide range of economic circumstances, and if the dividend payout is sustainable. Above all, we're glad to see that Chemical Industries (Far East) pays out a low fraction of its earnings and, while it paid a higher percentage of cashflow, this also was within a normal range. Unfortunately, the company has not been able to generate earnings growth, and cut its dividend at least once in the past. While we're not hugely bearish on it, overall we think there are potentially better dividend stocks than Chemical Industries (Far East) out there.

Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. To that end, Chemical Industries (Far East) has 3 warning signs (and 1 which is concerning) we think you should know about.

If you are a dividend investor, you might also want to look at our curated list of dividend stocks yielding above 3%.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read more:
Should You Buy Chemical Industries (Far East) Limited (SGX:C05) For Its Dividend? - Yahoo Finance

Pandemic Pivot: From face shields to hand sanitizer, chemical manufacturers are using tech to quickly produce COVID-19 necessities. – IndustryWeek

In a world where the unprecedented has become commonplace, the global chemical industry is in the midst of a massive pivot in response to the escalating COVID-19 pandemic.

Manufacturers that normally make fuel-grade alcohol are switching gears to produce neutral alcohol for disinfectants. Companies have diverted tankers full of isopropyl alcohol (IPA) to epicenters of the outbreak so it could be utilized to produce hand sanitizer. Plastics manufacturers that typically produce Mylar for hockey and lacrosse masks were instead making it for medical shields. One manufacturer, Ineos, the largest European producer of IPA and ethanolthe two raw materials needed to make hand sanitizersaid it would build three new factories in the span of 10 days, each capable of producing one million bottles of hand sanitizer per month, manufactured according to the specifications of the World Health Organization and specially designed to kill bacteria and viruses.

They were among dozens of chemical companies that were ramping up production, rallying their supply chains and adjusting their manufacturing operations in response to urgent calls for hand sanitizer, personal protective equipment, protective screens and other products.

Heres a look at several of the Industry 4.0 and Industrial Internet of Things (IIoT) digital capabilities that enabled companies to execute these types of pivots in the name of helping communities and people:

Connected, enterprise-wide operational intelligence. A manufacturer can continue to operate efficiently even during a major crisis-induced pivot when its entire enterprise is digitally connected and able to access and share real-time insight (such as via a robust ERP and/or CRM platform). With the ability to remotely monitor and manage raw material stocks with IIoT sensors, etc., a company can optimize stock levels to be lean yet still responsive enough to answer demand signals from a customer thats orchestrating its own pivot into a new product like face shields for medical applications.

Maybe, to meet the demands of a medical application instead of a sports application, those face shields require a different plastic formulation. Based on specifications provided by the shield manufacturer, the company supplying it with polyethylene terephthalate (PET) could immediately engage its R&D and engineering teams to tweak the molecule as needed and develop processes to produce that formulation.

Information about parameters and processes for producing the specific PET formulation needed for the face shields would then flow directly to the plant floor, the digital platform communicating the new parameters and processes to the reactor and other connected production equipment, enabling the manufacturer to quickly ramp up production of the new PET formulation, and to do so in a capital- and resource-efficient manner.

The ability to communicate, collaborate and adapt across a supply chain. As accustomed as chemical manufacturers are to B2B relationships, the COVID-19 crisis in some instances has required them to extend those relationships to the end consumer. In order to pivot their businesses to assist in meeting the publics urgent need for various products, chemical companies needed a better understanding of not just their direct B2B customers, but also their customers customersthe companies making medical visors, plastic shields and other products that have been in particularly high demand during the pandemic.

A highly networked and data-responsive system provides real-time supply and demand information at each point in the supply chain, which can be used to inform production and logistics decisions as circumstances change, down to the hour. Manufacturers can adjust or bolster production in response to surges in demand for certain materials, looping government, healthcare and other entities into the ongoing digital supply chain conversation.

Eastman was able to send an infusion of PETG film, a co-polyester commonly used for rigid medical packaging and medical devices, just in time to replenish the supply for a 3-D printing COVID-19 partnership involving the Tennessee Higher Education Commission and Austin Peay State University. The infusion came just as the partnership was running out of acetate sheet to make 10,000 urgently needed face shields for medical providers in Nashville. With insight into stock levels at its manufacturing facility in Kingsport, Tenn., the company could identify how much of the PETG film it could supply, when, then work with its new partners to get the material to them promptly.

Rapid modeling and prototyping capabilities. Premium machine learning- and AI-driven predictive tools enabled chemical manufacturers to quickly digest huge amounts of data to predict the performance and behavior of the formulations they were developing to meet pandemic-generated spikes in demand. These types of capabilities could, for example, enable a company like Ineos to model various formulations of hand sanitizer to confirm it can create one with the properties to kill bacteria and viruses.

Connected logistics. The COVID-19 crisis has underscored just how critical digitally connected logistics are to a manufacturers responsiveness and contingency planning. With the ability to monitor and manage inventory levels and location, as well as connected transportation and distribution assets, in real time, a manufacturer could respond in short order to supply and demand signals, then act in concert with its supply chain partners, government entities and healthcare providers to coordinate a timely response and cooperatively manage logistics so products could get where they needed to be expeditiously. Its how Eastman was able to deliver acetate sheet to Tennessee in a pinch.

As the COVID-19 pandemic holds the world in its grip, these kinds of advanced digital capabilities are enabling chemical manufacturers to pivot their production assets, their operations and their supply chains to meet the highly fluid and urgent needs of communities in crisis, and do so in ways they likely never imagined just a few weeks ago.

David Dunn has a degree in chemical engineering and has spent his 35-year career in and around the chemical industry. He has held numerous positions in the industry and developed a strong background in manufacturing, operations and product development. He joined SAP in 2007 as an industry principal for Chemicals and after a short time with SAP partners, he has rejoined SAP in 2020 as global industry marketing lead for Chemicals..

Main photo: A MakerBot producing face shields at Austin Peay State University.

Original post:
Pandemic Pivot: From face shields to hand sanitizer, chemical manufacturers are using tech to quickly produce COVID-19 necessities. - IndustryWeek

Japanese chemistry professor shows why three kinds of masks could be effective against the virus – SoraNews24

A helpful science experiment shows that masks, whether bought in a store or made at home, can help protect you against coronavirus.

People in China, Korean, and Japan have always used masks as protection against the common cold, the flu, and even seasonal allergies. With the coronavirus outbreak, though, the rest of the world is coming around to the idea of wearing masks when out, with national governments outside Asia starting to recommend their use, but theres some debate. Are masks really effective protection against the virus?

Thankfully, theres science to help us figure it out! Dr. Tomoaki Okuda, Associate Professor of Applied Chemistry at Keio University, did an experiment that measured the amount of particles in the air without a mask, with a surgical mask, with a homemade paper towel mask, and with a mask made from a cloth handkerchief. Essentially, he tested whether masks of each of the three varieties were effective at blocking particles in the air, and the results were pretty interesting.

For his experiment, Okuda used a Scanning Mobility Particle Sizer (SMPS), whose hose sucks in the air of the room and measures its concentration of particles per cubic centimeter. Okuda set it to only look for the concentration of particles that are around the estimated size of the virus, which is believed to be between 20 and 100 nanometers in diameter.

The screen of the SMPS displays a chart that shows the concentration of particles per cubic centimeter on the vertical axis, and the size of particles on the horizontal axis. In short, the resulting graph bars show the concentration of each particle diameter per cubic centimeter.

As a control experiment, Okuda ran the hose without anything covering it, and the SMPS measured about 6,000 particles per cubic centimeter of air in the room that are between 10 and 150 nanometers in size. Now, imagine that youve come in contact to someone who is contagious with the disease, and among the 6,000 particles per cubic centimeter youre breathing in, there are a fair amount of virus particles in the air. Without anything covering your mouth and nose as you breathe in, the chance of you being infected could be pretty high, right?

So, Okuda tried wrapping an ordinary surgical mask, like those sold in drug stores, around the top of the hose. The air that the SMPS measured now had significantly lower amounts of particles than before; somewhere around 1,800 per cubic centimeter. Okuda estimates that this means that surgical masks are able to collect about 60-70 percent of particles of that size. That means that the majority of virus particles wont make it through the mask as youre breathing in.

Then Okuda tried a mask made out of three paper towels that had been folded in half; essentially the same as six layers of paper towels that have been stacked one on top of the other. Surprisingly, the paper towels were more efficient at catching particles than the surgical masks. According to the SMPS, the air sucked through the paper towel mask had only about 1,000 particles of that size per cubic centimeter, with a collection efficiency rate of about 80 percent.

The paper towels also seemed particularly effective on much smaller particles.

In the final experiment, Okuda used a handkerchief that had been folded over three times. When placed over the SMPS hose, it had a similar effectiveness as the surgical mask, reducing the particles in the air down to 1,800 particles per cubic centimeter. Though he doesnt specify what kind of fabric his handkerchief was made of, we might guess that it was a more common variety of cotton or polyester, which those of us ordinary people could find easily.

Okuda did mention that the virus particulars are smaller than the gaps between the fibers of a mask, but he said they arent likely to slip between the fibers because they move in Brownian motion. Essentially that means they dont move in a straight line, but randomly, because they are bumping into the molecules in the air. Because of that, the likelihood of them moving straight between the fibers is low, and theyll likely get caught among the fibers of whatever material was used to make the masks.

So there you have it! Science seems to indicate that masks are reasonably effective at catching particles that are the same estimated size is the COVID-19 virus. You might notice that 60 to 80 percent isnt completely effectivebut thats still significantly less COVID-19 viruses you could potentially be breathing in, and at any rate, with a mask youll probably be touching your face less, too, so it seems worth trying if you really want to protect yourself and those you love.

Cant find any masks at your local drug stores? Dont worry, Twitter taught us how to make one using paper towelsthough we might suggest using more than one sheetand the Daiso was kind enough to show us how to make one out of cloth, so there are several options available for you. And dont forget to study up on the right way to wear a mask before you go out!

Source, images: YouTube/Tomoaki OKUDA Want to hear about SoraNews24s latest articles as soon as theyre published? Follow us on Facebook and Twitter!

Like Loading...

View original post here:
Japanese chemistry professor shows why three kinds of masks could be effective against the virus - SoraNews24

Chemist Remains Optimistic About Success of Antiviral in Treating COVID-19 – Pharmacy Times

The Liu group at Texas A&M University, led by chemist Wenshe Ray Liu, PhD, identified the antiviral drug remdesivir as a viable treatment for coronavirus disease 2019 (COVID-19) in January.1 Remdesivir was originally developed as a treatment for Ebola in 2014, but upon the surge of COVID-19 in Wuhan, China, before the virus spread throughout the rest of the world, the Liu group investigated its use in treating COVID-19.1

The motivation that drove us was the rush against time to find alternative medicines that might be put in use to fight against the virus when it spread to the United States, Liu said in an article in Texas A&M Today.2

Following the Liu groups research, remdesivir has been tested in at least 5 large-scale clinical trials around the world and has been delivered to some patients, including the first confirmed COVID-19 patient in the United States on January 21 in Washington state.2 After treatment with remdesivir, that patient successfully recovered.2

Although Liu remains convinced that remdesivir is the right drug to treat COVID-19, he explained in the interview that due to the reports of multiple strains of COVID-19, success in treating the coronavirus should not be viewed as following a single approach.2

Despite his caution, Liu explained further, Remdesivir is still the best and probably the only option to target the virus directly in patients.2

With the clinical trial studying remdesivir in the United States set to finish this week, Liu remains optimistic that the results of the study will prove the treatments efficacy.2 However, he also acknowledges that in the wide-scale use of any virus treatment, drug-resistant virus strainsare likely to develop.2 This may be especially true for COVID-19, since multiple strains of the coronavirus have been reported to exist already.2

The infectivity of the original strain shown in Wuhan was not as high as what we have observed for the current strain in the United States, he said in the interview, adding that, At this stage, the scientific community needs to prepare for the worst and work to bring other treatment options to the forefront.2

References

Go here to read the rest:
Chemist Remains Optimistic About Success of Antiviral in Treating COVID-19 - Pharmacy Times

Here’s what Post Malone fronting My Chemical Romance would sound like – Alternative Press

If you were a fan of the Hawthorne Heights and Post Malone I Fall Apart In Ohio mashup, then get ready for one better. YouTuber Call it Clarity just gave us a Posty and My Chemical Romance mashup to end all others.

The newest song takes Post Malones Circles and brilliantly combines it with My Chemical Romances I Dont Love You. Unfortunately, this one doesnt have a clever name, but it does provide a bit of humorous escape in these desperate times.

Mashups and covers are always fun. Pretending to live in another universe where blink-182 wrote a the Killers Mr. Brightside or Slipknot and NSYNC somehow synced up is a blast.

Now we have the newest content for our ears to enjoy with I Dont Love You/Circles.

The new mashup, for the most part, superimposes Post Malones vocals over My Chemical Romances I Dont Love You instrumentals, with a few Gerard Way vocal surprises tucked in there. Check it out below.

This isnt the first time Post Malone has been associated with the guys in MCR.

The rapper actually played the emo anthem Welcome to the Black Parade at Emo Nite in June of 2017. Check out the video of him rocking out to the MCR bop below.

Post-hardcore iconsA Day To Rememberand rap superstarPost Malonedont usually come up in the same sentence. They especially dont pop up in the same song. We think its safe to say that a collaboration between the two would be pretty rare. Enter the wonders of the internet.

One dedicated fan decided to contribute something we all loved. The audio mixologist created amashupbetween If It Means A Lot To You by A Day To Remember and Better Now by Post Malone. Check it out below.

From combiningPost Malone and Hawthorne Heightsto mashing togetherTaylor Swift and Fall Out Boy, mashups have been defying genres to create tracks we never knew we needed.

YouTuber Call It Clarity has made a few mashups before, mainly of two scene bands such asFall Out BoyandMy Chemical Romance. But they also love combining Posty with emo bands such asHawthorne Heights.

Both songs were incredible before, but now, If It Means Im Better Now is the perfect song for fans of every genre to cry to. Check it out below.

Tell us your favorite mashup in the comments below!

Read the original here:
Here's what Post Malone fronting My Chemical Romance would sound like - Alternative Press

LSU chemists preparing large batches of hand sanitizer – WBRZ

').parent().insertBefore($(".rsNav.rsThumbs.rsThumbsHor"));var captionWrap = caption.parent();var slider = $(".royalSlider").data('royalSlider');slider.ev.on('rsBeforeAnimStart', resizeCaption);function resizeCaption(){captionWrap.stop(true);captionWrap.animate({height: caption.height()}, 250);};resizeCaption();});

BATON ROUGE - An LSU chemist has spent the last several weeks helping prepare thousands of gallons of hand sanitizer to be used in Louisiana.

Ph.D. student Anthony Mai and his advisor, LSU Chemistry Chair John Pojman, are ensuring the quality of over 5,000 gallons of hand rub sanitizer. Last week, the first two batches were placed into 5,300 bottles and distributed all over the state. Mai worked in the chemical industry before entering LSUs graduate program and is familiar with working with such large-scale amounts of liquid chemicals.

This week, the chemists and workers at the Elayn Hunt Correctional Centers soap plant warehouse mixed and bottled thousands more of the sanitizer that will be used to fight the spread of coronavirus.

Read the original post:
LSU chemists preparing large batches of hand sanitizer - WBRZ

Frontiers in Neurology Publishes Study Evaluating Remote Electrical Neuromodulation (REN) As Viable Alternative to Drugs for Acute Migraine – P&T…

NETANYA, Israel, April 7, 2020 /PRNewswire/ --Theranica Bioelectronics (Theranica), a bio-medical technology company developing advanced electroceuticals for migraine and other pain conditions, announced today that Frontiers In Neurology Journal published an article demonstrating that incorporating Remote ElectricalNeuromodulation (REN)treatment into usual care of migraine has the potential to reduce reliance on acute pharmacological medications.

"This study signals a potentially significant shift in how we approach the acute treatment of migraine," said lead author Michael Marmura,MD, HeadacheSpecialist at the ThomasJefferson UniversityHospital in Philadelphia. "Adding REN as an alternative to traditional migraine treatments opens the door to new long-term treatment strategies. What is most promising is the fact that so many patients in the study chose REN without being specifically prompted, and experienced treatment outcomes similar or slightly better than their usual care."

In a cohort of 117 patients who were given the option of using REN in addition to or instead of their usual care treatments, such as triptans or over-the-counter (OTC) medications, 89.7% used REN exclusively, without medications. When REN was not available, only 15.4% chose to avoid medications in all their reported migraine attacks. The patients who used REN exclusively reported similar treatment outcomes to their usual (pharmacological) care. The article concludes that "Incorporating REN into usual care may have a positive impact on migraine management by reducing the reliance on acute medications."

"When patients experience debilitating migraine symptoms, they are looking for effective relief," said Dr. Morris Levin, chief of the headache medicine division and director of the Headache Center at UCSF Medical Center in San Francisco, who served as the chairman of the independent Data and Safety Monitoring Committee of the study. "Traditionally we've had only a limited number of useful acute migraine treatments, many of which have side effects. REN is a welcome option, due to its apparent safety and almost nonexistent adverse effects. In addition, the risk of medication overuse, often a limiting factor with acute medications, should not be an issue when using a drug free therapy such as REN."

The device used in the study was Theranica's FDA-authorized prescribed therapeutic wearable, Nerivio. The device deploys REN to activate the body's native Conditioned Pain Modulation (CPM) mechanism to treat pain and accompanying migraine symptoms. Nerivio, which was recently named one of TIME's best inventions of 2019, is available in the US with a valid prescription. It is also accessible via online telemedicine portals Coveor UpScript, which provide physician consultations and home delivery.

About Theranica

Theranica Bio-Electronicsis dedicated to creating effective, safe, affordable, low-side effect electroceuticals for idiopathic pain conditions.The company's award-winning flagship product,Nerivio, is thefirst FDA-authorized smartphone-controlled prescription wearable device for acute migraine treatment.Setting the foundation of an effective first-line therapeutic alternative to pharmacological options within the migraine industry, Theranicais expanding its proprietary technology to offer additional solutions for other pain conditions.

Learn more by visiting our website,www.theranica.comand following us on LinkedIn, Twitter and Facebook.

Media Contact: Ellie Hanson Finn Partners ellie.hanson@finnpartners.com +1-929-222-8006

Theranica Contact: Ronen Jashekronenj@theranica.com+972-72-390-9750

View original content:http://www.prnewswire.com/news-releases/frontiers-in-neurology-publishes-study-evaluating-remote-electrical-neuromodulation-ren-as-viable-alternative-to-drugs-for-acute-migraine-301036767.html

SOURCE Theranica

Go here to see the original:
Frontiers in Neurology Publishes Study Evaluating Remote Electrical Neuromodulation (REN) As Viable Alternative to Drugs for Acute Migraine - P&T...

Patients With Newly Diagnosed Multiple Sclerosis More Likely to Have Impaired Cognitive Performance – Neurology Advisor

Compared to the general population, patients with newly diagnosed multiple sclerosis (MS)/clinically isolated syndrome (CIS) are more likely to have impaired cognitive function, a study in Neurology suggests. The study also found that being black and Hispanic, not having a university degree, and having a relatively low household income are predictors of cognitive performance.

A total of 1174 adults with MS/CIS (mean age, 40.7 years) who were enrolled in the MS Sunshine Study were included in this analysis. The researchers administered the oral Symbol Digit Modalities Test (SDMT) during a structured in-person assessment to identify cognitive impairment in incident cases of MS/CIS (n=554) and matched controls (n=620). Additionally, verbal fluency was also determined. A multivariable linear regression was used to examine the association between SDMT scores and race/ethnicity and MS. Multivariable analyses were adjusted for age at time of interview, sex, education, and household income.

Across all racial/ethnic groups, patients with MS/CIS had significantly lower mean SDMT scores compared to controls (52.2 vs 58.3, respectively; P <.0001). The multivariable linear regression analyses, independent predictors of lower oral SDMT scores included being black (,5.97; P <0.0001) or Hispanic (,3.06; P <0.0001), having MS (,6.04; P <.0001), lower educational attainment (high school, trade school, or less: ,5.02; P <.0001), and having a household income $65,000 (,5.02; P =.0007). The researchers observed no interaction between MS case status and race/ethnicity on SDMT scores.

The authors note that these analyses may have been limited by the inclusion of only participants from California and the lack of ethnic diversity among the black and Hispanic participants.

The investigators suggest that in addition to optimizing disease-modifying treatments to slow cognitive decline in patients with MS, interventions aimed at improving cognition may also be beneficial. From a societal perspective, improving opportunities for higher educational attainment and higher incomes for black and Hispanic participants in the United States would likely reduce racial/ethnic disparities in cognitive performance.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Amezcua L, Smith JB, Gonzales EG, Haraszti S, Langer-Gould A. Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis [published online March 9, 2020]. Neurology. doi: 10.1212/WNL.0000000000009210

View post:
Patients With Newly Diagnosed Multiple Sclerosis More Likely to Have Impaired Cognitive Performance - Neurology Advisor

First Case of COVID-19 Presenting as Guillain-Barr Reported – Medscape

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

Physicians in China are reporting what they believe is the first case of COVID-19 initially presenting as acute Guillain-Barre syndrome (GBS). The patient was a 61-year-old woman returning home from Wuhan during the pandemic.

"GBS is an autoimmune neuropathy, which could be triggered by various infections," corresponding author Sheng Chen, MD, PhD, Shanghai Jiao Tong University School of Medicine, China, told Medscape Medical News.

However, "Our single case report only suggests a possible association between GBS and SARS-CoV-2 infection. It may or may not have a causal relationship," Chen noted.

The case study was published online April 1 in Lancet Neurology.

The female patient returned from Wuhan on January 19 but denied having any fever, cough, chest pain, or diarrhea. She presented on January 23 with acute weakness in both legs and severe fatigue that progressed.

At presentation, temperature was normal, oxygen saturation was 99% on room air, and the patient's respiratory rate was 16 breaths per minute. She was not tested for SARS-CoV-2 at that point.

A neurologic examination revealed symmetric weakness (Medical Research Council grade 4/5) and areflexia in both legs and feet. The patient's symptoms had progressed 3 days after admission, and testing revealed decreased sensation to light touch and pinprick.

Admission laboratory test results indicated a low lymphocyte count and thrombocytopenia. Results of nerve conduction studies performed on day 5 of hospitalization were consistent with demyelinating neuropathy.

She was diagnosed with GBS and given intravenous immunoglobulin. On day 8, she developed a dry cough and fever, and a chest CT showed ground-glass opacities in both lungs. At this point, she was tested for SARS-CoV-2, and the results were positive.

The patient was immediately transferred to an isolation room and received supportive care and antiviral drugs. Her condition improved gradually, and her lymphocyte and thrombocyte counts were normalon day 20.

At discharge on day 30, she had normal muscle strength in both arms and legs, and tendon reflexes in both legs and feet had returned. Her respiratory symptoms had resolved as well. A second SARS-CoV-2 test was negative.

Two relatives of the patient who had been with her during her hospital stay also tested positive for SARS-CoV-2 and were isolated and treated.

All of the hospital staff that cared for the patient, including two neurologists and six nurses, tested negative for SARS-CoV-2.

Given the temporal association, SARS-CoV-2 infection could be responsible for the development of GBS in this patient, the investigators note. They add that the onset of GBS symptoms overlapped with the period of SARS-CoV-2 infection.

"Hence Guillain-Barre syndrome associated with SARS-CoV-2 might follow the pattern of a parainfectious profile, instead of the classic postinfectious profile, as reported in Guillain-Barre syndrome associated with Zika virus," the researchers write.

"More cases with epidemiological data are necessary to support a causal relationship" between SARS-CoV-2 infection and GBS, said Chen.

"However, we still suggest physicians who encounter an acute GBS patient from a pandemic area protect themselves carefully and test [for the] virus on admission. If the result is positive, the patient needs to be isolated," Chen said.

Lancet Neurol. Published online April 1, 2020. Full text

For more Medscape Neurology news, join us on Facebook and Twitter.

Continued here:
First Case of COVID-19 Presenting as Guillain-Barr Reported - Medscape

Biologist Carl Bergstrom on coronavirus, misinformation and why we weren’t prepared – CNBC

Carl Bergstrom is an infectious disease expert who's been thinking about the relationship between biology and social systems. One central theme in his work is information: How it flows and how it spreads.

At the University of Washington, where he lectures, he developed an online course called "calling bull----" to help students use critical reasoning to see through false health information.Off the back of the syllabus' popularity, Bergstrom and his colleague Jevin West wrote a book filledwithadviceabouthow mainstream audiences can use statistics and other data science tools to question hyped-up products and conspiracy theories that are pervasive on our social media feeds today.

There are a lot of information gaps when it comes to the COVID-19 virus. And Bergstrom is one of the scientists desperately trying to fill those gaps.

He says that early on, some of the information coming out of China felt like misinformation because it was coming from political opponents of the Chinese government, but it turned out to be "partially right." Since then, he's been noting and occasionally debunking various conspiracy theories and rumors, such as the idea that the coronavirus was a Chinese bioweapon -- and, in China, that it's a U.S. bioweapon -- and false stories of catastrophes at American hospitals. On Twitter, he also called out a neurologist, Scott Mintzer, for a "panic inducing" thread about a health system in Seattle, which was based on a second-hand account from an unnamed doctor.

Bergstrom also says that there's been plenty of anticipation of a respiratory viral pandemic like COVID-19, but he does not blame the slow response in the U.S. entirely on the current government. Rather, he notes it's politically challenging to fund pandemic preparedness without a clear and present threat.

"There was a denial and refusal to act that lost us some time, and that's part of what happened. But we also didn't have the resources in place to respond to a pandemic in terms of our coordination structure," Bergstrom said. "There's a 'not on my watchism,' which involves a choice between doing a politically unpopular thing to provide funding for pandemic preparedness that might not come, or avoid doing that and slash whatever is there. These are perceived as once-in-a-century catastrophes."

He argues that the government must play a central role in planning and responding to such catastrophes, and that advocates of small-government philosophy should understand this kind of planning is akin to raising a military.

"There are some collective action problems that even the Chicago-school economists acknowledge will not be adequately solved by the market," he says. "No one expects us to raise a powerful standing army based on private market forces (and) we consider that a central role of the government to provide national defense. Pandemic preparedness is the same."

He also suggests that current lockdowns may need to last past the summer in some areas, unless we can increase testing capacity.

"My personal feeling is that we either have a long lockdown ahead of us, or we'll get testing capacity way up."

Here's a transcript of the interview, edited for length and clarity:

FARR: Given that you track how information spreads, both true and false, where and when did you see the first groups really start to sound the alarm on this?

BERGSTROM: Interestingly, we saw some loud voices early on coming from organized campaigns from political opponents of the Chinese government. There was both a lot of hyperbole but also some truth to what they were sharing. It was feeling like misinformation at the time, but turned out to be partially right. By mid-January, I was having a lot of conversations with others in the infectious disease community, but we didn't yet have diagnosed community transmission. By February, we knew it was a real problem.

FARR: What are some of the most concerning and prevalent hoaxes or false rumors that you're seeing? Can you share your top five?

CARL BERGSTROM: There's the idea that this virus is a Chinese bioweapon. Often (I've seen) a very quickly retracted paper referenced that claimed to have found big pieces of the HIV genome in the SARS-CoV-2 genome. That was debunked within 48 hours.Interestingly, a Chinese colleague told me that in China there is a very widely spread rumor on social media that it is a U.S. bioweapon, but I do not have documentation of this. There has been a lot of talk about the SO2 levels over Wuhan, linking it purportedly to the mass incineration of bodies. There is all the 5G stuff, but I haven't even gone down that rabbit hole. And there idea that Bill Gates is somehow involved, in creating and spreading the virus, not fighting it.

Finally, there were a rash of false second-hand narratives of catastrophes at hospitals. Some are spread by well known, credentialed people. I debunked one of those from the prominent neurologist on March 15th (The neurologist Scott Mintzer deleted an alarmist post after Bergstrom pointed out flaws with a second-hand account).

FARR: As a biologist, when did you first start to personally become concerned about COVID-19?

BERGSTROM: We have a mailing list for many of us professionals in the infectious disease world. You'll see clusters of disease every so often, which we'll share. In this case, we were concerned but the the information from China in those first months wasn't great. The bottom line is that by the time things got bad in Wuhan, infectious disease professionals knew that given the size of the city and the frequent travel to the rest of the world, it would get out. We didn't know if it would turn pandemic, because there have been cases where we've stamped out little fires as they emerge.

FARR: Could we have acted much sooner in the U.S., say in late January when the picture started to become more clear about how serious of a threat this was?

BERGSTROM: There was a denial and refusal to act that lost us some time, and that's part of what happened. But we also didn't have the resources in place to respond to a pandemic in terms of our coordination structure. There was definitely planning and investment that could have been done. I was most active in these sorts of discussions in the Bush years. During that period, there was a big debate about the role of government in public health and a reluctance to invest too heavily in pandemic planning. But I argued that there are some things the government has to provide. For me, that would include the research and surveillance tools, but also the infrastructure you need for rapid vaccine production.

FARR: So the government is really responsible, and not the private sector...

BERGSTROM: I'm not saying that the government should provide pandemic planning because I want a welfare state. There are some collective action problems that even the Chicago-school economists acknowledge will not be adequately solved by the market. No one expects us to raise a powerful standing army based on private market forces (and) we consider that a central role of the government to provide national defense. Pandemic preparedness is the same.

FARR: How come we were so unprepared for this, especially when it comes to having insufficient supplies of masks and personal protective equipment?

BERGSTROM: There's a 'not on my watchism,' which involves a choice between doing a politically unpopular thing to provide funding for pandemic preparedness that might not come, or avoid doing that and slash whatever is there. These are perceived as once-in-a-century catastrophes.

FARR: You've been researching pandemics throughout your career. Did you have a fear around respiratory viruses in particular?

BERGSTROM: I don't know why people don't talk more about the potential for a GI (gastrointestinal) pandemic. It's something I'm going to be asking about. I have also researched pox viruses. Monkeypox, with a few mutations, could become quite a bad thing. But it's these respiratory ones we keep seeing again and again. The story of the past twenty years has been SARS (severe acute respiratory syndrome), and all of these smaller outbreaks, and any one of them could have flared into a disaster. It made sense to expect that something like this COVID-19 pandemic could happen.

FARR: I've read some articles pointing to folks like Bill Gates who seemed to have seen this coming. Were they prescient, or just following the data?

BERGSTROM: Well, we had a pandemic 11 years ago (with H1N1). And there are others going back further in time. People forget the severity of the 1957 flu pandemic. There really isn't an excuse to be caught unprepared, but there's certainly no excuse going forward.

FARR: Now that we're here and we're in this, do we have some tough choices to make? Do you suspect that citizens are going to be asked to make tradeoffs when it comes to privacy and civil liberties? In China, you saw temperature checks of passers-by and at buildings, and other invasive surveillance measures.

BERGSTROM: Without widespread testing, even those measures won't be effective. My personal feeling is that we either have a long lockdown ahead of us, or we'll get testing capacity way up. With temperature checks, I suspect you'd miss a lot of asymptomatic cases so I'm really in two minds about it.

But another consideration is that we already allow ourselves to be tracked in unimaginable ways so that companies can sell ads. If it came to it, we might be asked to consider whether we'd be willing to be tracked via some surveillance measures to go back to work. I might opt in because I'm a public health professional with a secure job, but I completely understand why others wouldn't. And I don't think you can impose (surveillance systems) on people in the U.S.

FARR: You've tweeted about the IMHE model, which shows projections of the spread of COVID-19, assuming full social distancing. You've also shared some reservations with these predictions. Can you elaborate?

BERGSTROM: If you believe that model, things are looking pretty good in states like Washington State by mid-May. But this is all predicated on us being successful at turning the curve around. If we do manage to get reasonable testing going and we keep following the social distancing guidelines, these models suggest life could return to normal come the summer. But if we fall short in either of those things, then we're going to be looking at some harder choices about whether we let a lot of people get infected or consider a longer lockdown.

FARR: Do we have the political will to consider the longer quarantine?

BERGSTROM: I really have no idea. In this pandemic, we don't currently have pharmaceutical measures in place, like a proven treatment. What we do have is traditional public health. We have work stoppages, stay at home orders, travel restrictions. And we also have misinformation that undercuts the trust of scientists and other authorities. There's a political pressure that is building up on our policymakers. I do hope people will do everything they can to get us on the right trajectory, but I also want us to be aware and planning for all possible outcomes.

WATCH: Bill Gates believes schools could reopen in the fall

Continue reading here:
Biologist Carl Bergstrom on coronavirus, misinformation and why we weren't prepared - CNBC

Five named SUNY Distinguished Professors – UB Now: News and views for UB faculty and staff – University at Buffalo Reporter

Campus News

UBNOW STAFF

Five UB faculty members have been named SUNY Distinguished Professors,the highest faculty rank in the SUNY system.

M. Laura Feltri, Jo Freudenheim, Amit Goyal, Elad Levy and Stephen Tiffany were appointed to the distinguished professor ranks by the SUNY Board of Trustees at its meeting on March 17.

The rank of distinguished professor is an order above full professorship and has three co-equal designations: distinguished professor, distinguished service professor and distinguished teaching professor.

The five were all named distinguished professors in recognition of their international prominence and distinguished reputations within their chosen fields. According to SUNY, this distinction is attained through significant contributions to the research literature or through artistic performance or achievement in the case of the arts. The candidates work must be of such character that the individuals presence will tend to elevate the standards of scholarship of colleagues both within and beyond these persons academic fields.

UB is tremendously proud that five of our most distinguished faculty members have been appointed to SUNYs highest rank, said A. Scott Weber, provost and executive vice president for academic affairs. This distinction recognizes that UB faculty are among the best in the world and have a transformative impact through their sustained research and scholarship contributions.

UBs newest SUNY Distinguished Professors:

M. Laura Feltri, SUNY Distinguished Professor of Biochemistry

Feltri, professor of biochemistry and neurology in the Jacobs School of Medicine and Biomedical Sciences and acting director of the Hunter James Kelly Research Institute, is an internationally renowned expert and pioneer in the study of myelin diseases in the nervous system. She conducts research on Schwann cells and disorders that affect the peripheral or central nervous systems, like Charcot-Marie-Tooth disease, multiple sclerosis or Krabbe leukodystrophy.

With the undergraduate, graduate and postdoctoral students she has mentored, Feltri has made numerous seminal discoveries in her field, including developing the first mutagenesis tool for studying Schwann cell development and the signals that regulate myelination. In collaboration with Lawrence Wrabetz, she pioneered the use of transgenic animal to model neurological diseases and develop new therapies.

An internationally recognized leader in the biology of nervous system myelination, her fundamental research is contributing to the development of novel therapies for neurological disorders.

Feltri serves as chair of the Cellular and Molecular Biology of Glia National Institutes of Health study session, as a board member of scientific organizations and on the editorial board of various journals.

Jo Freudenheim, SUNY Distinguished Professor of Epidemiology and Environmental Health

Freudenheim, UB Distinguished Professor and chair of the Department of Epidemiology and Environmental Health in the School of Public Health and Health Professions, is an internationally renowned expert in cancer epidemiology. She has conducted seminal research to understand factors that influence risk for cancer, particularly breast cancer, including the role of diet, alcohol and the physical environment. She uses a variety of methodologically rigorous approaches (e.g., molecular epidemiology) to examine carcinogenesis, from the molecular level to the individual and population levels.

Her research has been funded for more than 25 years by the NIH and other federal funding agencies. She has authored more than 275 peer-reviewed publications in national and international high-impact journals, where they have helped shape the field of chronic disease epidemiology.

A frequent reviewer for such entities as the National Cancer Institute, the American Cancer Society and the Canadian Foundation for Innovation, she also has contributed to the field by serving as a mentor to graduate students and postdoctoral fellows, and in her role as director of a cancer epidemiology training program.

Amit Goyal, SUNY Distinguished Professor of Materials Science

An internationally recognized materials scientist, Goyal is a SUNY Empire Innovation Professor and founding director of UBs RENEW Institute. In 2018, he was elected to the National Academy of Engineering for groundbreaking scientific advances and technological innovations enabling the worldwide commercialization of high-temperature superconductors. He is also a fellow of the National Academy of Inventors, with 87 issued patents and additional patents pending.

Goyal joined UB in 2015 to direct RENEW, an institute that harnesses the expertise of more than 100 faculty in seven UB schools and colleges to explore solutions to globally pressing energy and environmental problems, as well as the social and economic issues connecting them. His leadership has placed UB at the forefront of efforts to reduce water and air pollution, and find innovative, clean ways to produce, transmit and store energy.

In 2019, he was awarded the UB Presidents Medal that recognizes outstanding scholarly or artistic achievements, humanitarian acts, contributions of time or treasure, exemplary leadership or any other major contribution to the development of the University at Buffalo and the quality of life in the UB community.

The author or co-author of more than 350 technical publications and co-editor of six books, Goyal was ranked by Thompson-Reuters Essential Science Indicators as the most cited author worldwide in the field of high-temperature superconductivity from 1999-2009. He is a fellow of eight professional societies: the American Association for Advancement of Science, the Materials Research Society, the American Physical Society, the World Innovation Foundation, the American Society of Metals, the Institute of Physics, the American Ceramic Society and the World Technology Network. He serves on several scientific advisory boards and on several National Academy review panels.

Elad I. Levy, SUNY Distinguished Professor of Neurosurgery

Levy, professor and chair of the Department of Neurosurgery in the Jacobs School, is an internationally renowned expert in stroke and cerebrovascular neurosurgery, and a major contributor to the service of organized neurosurgery. Widely regarded as one of the pioneers in this field, Levy has published extensively and developed new technology and approaches that have been instrumental in helping treat people around the world with previously incurable cerebrovascular disorders.

A member and fellow of the American Association of Neurological Surgeons, the American College of Surgeons and the American Heart Association/American Stroke Association, Levy has achieved additional national and international prominence as one of 100 members of the American Academy of Neurosurgery and one of 12 members of the American Board of Neurosurgery.

He serves as secretary of the Congress of Neurological Surgeons and director of the American Board of Neurological Surgery.

Stephen Tiffany, SUNY Distinguished Professor of Psychology

The Empire Innovation Professor in the Department of Psychology, Tiffany is world-renowned expert on the study of addictions, developing theoretical models that have shaped the way experts in the field conceptualize the relationship between craving and addictive behavior.

Actively involved in numerous clinical studies many of which focus on nicotine Tiffany conducts empirical research with people and animal models using a combination of controlled experimentation and more translational work. He provided a dominant theoretical perspective on craving and its relationship to drug use with his 1990 Psychological Review paper that outlined a cognitive model of craving now referred to as the Tiffany model.

An extraordinarily productive and prolific researcher, Tiffany has more than 100 publications in highly prestigious journals and has received multiple grants from the National Science Foundation and the NIH.

He has served as a standing member of three different NIH review panels and on the editorial boards of multiple journals.

A UB faculty member since 2007, Tiffany served as chair of the Department of Psychology from 2011-18.

View post:
Five named SUNY Distinguished Professors - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter

Neurovascular or Interventional Neurology Devices Market Business Opportunities, Current Trends and Growth Forecasts by 2025 | Stryker, Medtronic,…

Chicago, United States: The global Neurovascular or Interventional Neurology Devices Market is expected to surge at a steady CAGR in the coming years, states the latest Report Hive Research. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Neurovascular or Interventional Neurology Devices market. Analysts have used Porters five forces analysis and SWOT analysis to explain the various elements of the market in absolute detail. Furthermore, it also studies the socio-economic factors, political changes, and environmental norms that are likely to affect the global Neurovascular or Interventional Neurology Devices market.

The Neurovascular or Interventional Neurology Devices market study published in the report is in a chapter-wise format to ease of the readability and complexity of the data covered. Each chapter is further categorized into its respective segments containing well-structured data. The competitive scenario displayed includes major market player details such as, company profile, end-user demand, import/export volume, sales data, etc. The report also covers the business strategies applied by different players, which will be a great addition for smart business decisions.

Get a Sample PDF Report: https://www.reporthive.com/request_sample/2258380

Top Key players cited in the report:

StrykerMedtronicJohnson and JohnsonTerumoPenumbraBoston ScientificAbbott LaboratoriesMerit Medical SystemsMicroport Scientific

The report on Neurovascular or Interventional Neurology Devices market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, etc. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Neurovascular or Interventional Neurology Devices.

The research report is committed to giving its readers an unbiased point of view of the global Neurovascular or Interventional Neurology Devices market. Thus, along with statistics, it includes opinions and recommendation of market experts. This allows the readers to acquire a holistic view of the global market and the segments therein. The research report includes the study of the market segments on the basis of type, application, and region. This helps in identifying segment-specific drivers, restraints, threats, and opportunities.

The scope of the Report:The research report on the global Neurovascular or Interventional Neurology Devices market is a comprehensive publication that aims to identify the financial outlook of the market. For the same reason it offers a detailed understanding of the competitive landscape. It studies some of the leading players, their management styles, their research and development statuses, and their expansion strategies.

The report also includes product portfolios and the list of products in the pipeline. It includes a through explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Global Neurovascular or Interventional Neurology Devices Market: Competitive RivalryThe chapter on company profiles studies the various companies operating in the global Neurovascular or Interventional Neurology Devices market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Neurovascular or Interventional Neurology Devices market participants in the past few years to remain ahead of the competition.

Global Neurovascular or Interventional Neurology Devices Market: Regional Segments

The chapter on regional segmentation details the regional aspects of the global Neurovascular or Interventional Neurology Devices market. This chapter explains the regulatory framework that is likely to impact the overall market. It highlights the political scenario in the market and the anticipates its influence on the global Neurovascular or Interventional Neurology Devices market.

Neurovascular or Interventional Neurology Devices Segmentation by Product

Cerebral Thrombectomy DevicesCarotid Artery Stenting (CAS) SystemCerebral Aneurysm and AVM Endovascular Embolization SystemsIntracranial Stent SystemsFlow Diverter for Aneurysm

Neurovascular or Interventional Neurology Devices Segmentation by Application

HospitalClinic

Get Customized PDF template of this report: https://www.reporthive.com/request_customization/2258380

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Neurovascular or Interventional Neurology Devices market

Chapter 2: Evaluating the leading manufacturers of the global Neurovascular or Interventional Neurology Devices marketwhich consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Neurovascular or Interventional Neurology Devices marketby regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Speak to Research Analyst: +1-312-604-7084

About Us:Report Hive Research delivers strategic market research reports, statistical survey, and Industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of United States Business Leaders, Government Organizations, SMEs, Individual and Start-ups, Management Consulting Firms, and Universities etc. Our library of 600,000+ market reports covers industries like Chemical, Healthcare, IT, Telecom, Semiconductor, etc. in the USA, Europe Middle East, Africa, Asia Pacific. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio and application analysis etc.

Read more:
Neurovascular or Interventional Neurology Devices Market Business Opportunities, Current Trends and Growth Forecasts by 2025 | Stryker, Medtronic,...

Roche’s Ocrevus Continues to Impress in the EU with Strong Uptake in New Start and Switch Multiple Sclerosis Patient Segments, but Novartis’ Mayzent…

In the wake of the Mayzent EMA approval, neurologists expect to diagnose more patients with active secondary progressive multiple sclerosis to broaden the pool of patients eligible for the second-to-market S1P receptor modulator, according to Spherix Global Insights

EXTON, Pa., April 9, 2020 /PRNewswire/ --Driven by expanded access to and uptake of disease-modifying therapies (DMTs) to treat advanced stages of relapsing multiple sclerosis (MS), the MS market in Europe shows signs of continued expansion of the number of patients treated with DMTs. Spherix collected data from 247 EU5 neurologists surveyed between February 5th and March 3rd for the most recent semiannual report included in Spherix's RealTime Dynamix: Multiple Sclerosis (EU) service. Findings confirm that the introductions of Roche's Ocrevus, Merck KGaA's Mavenclad, and (most recently) Novartis' Mayzent have contributed to the growth in treatment rates for relapsing remitting MS (RRMS), active secondary progressive MS (SPMS), and primary progressive MS (PPMS). Ocrevus has shown tremendous ability to usurp historical mainstays just two years after its initial launches in Europe, the anti-CD20 monoclonal antibody (mAb) has replaced glatiramer acetate (GA) as one of the most preferred DMTs on the market. Generic alternatives to Copaxone could have cut back on the erosion of the GA class, but Teva's success in patent litigation and continued Copaxone brand loyalty have minimized generic disruption. Indeed, steady declines in overall GA share reveal that the first generics in the MS market have struggled to establish a foothold capable of buoying the class back to its historical level of popularity.

Invest In Intelligence That Delivers

Increasing use of Ocrevus in patients starting on a DMT for the first time, as well as patients switching to a different brand, are both driving Ocrevus' quickly rising reported share in MS. Within the segment of new start patients, Biogen's Tecfidera and Sanofi's Aubagio are currently the share leaders, as neurologists have become accustomed to relying on the convenience of oral DMTs for their MS patients initiating DMT treatmentespecially in France. However, with many neurologists favoring induction treatment, in which new patients are initiated on an aggressive approach with a high efficacy agent, Ocrevus is an increasingly popular option for patients starting on DMT treatment. In the UK, where induction treatment is especially common, the rise of Ocrevus use in new start patients accompanies a corresponding drop in Tecfidera use among the same group, threatening the latter DMT's dominance in early lines of therapy.

Among switch patients, Ocrevus is now the most prescribed therapy, besting Novartis' Gilenya and Biogen's Tysabri. With European Medicines Agency (EMA) restrictions placed on use of Sanofi's Lemtrada beginning in November 2019, prescribing of Lemtrada as a switch-to agent has dropped significantly, and overall preference for and reported share of the DMT have fallen. Neurologists now appear to be replacing prior use of Lemtrada with more prescribing of Ocrevus, especially in Germany, Italy, and Spain. Tecfidera, the second most frequently prescribed switch-to agent just one year ago, has also experienced a substantial contraction of reported share in France and Germany.

Story continues

Ocrevus' growth trajectory has been impressive and sustained over the past two years, but new and emerging agents are poised to abate its increasing dominance. Approved by the EMA on January 13th, just weeks before survey fielding, Novartis' Mayzent is now the only therapy, besides Bayer's Betaferon, indicated specifically for the treatment of active SPMS. Given the decline of interferon shares and the desire to use high-efficacy treatments for patients with advanced disease, neurologists expect that Mayzent's true competition will be with Ocrevus. Indeed, audit data from 1,266 charts of EU patients recently switched to a new DMT, analyzed as part of Spherix's RealWorld Dynamix: DMT Switching in Multiple Sclerosis (EU) service, showed that Ocrevus was the active SPMS switch segment leader. Early perceptions among neurologists suggest that Mayzent could become a key option for active SPMS. More than half of EU neurologists are extremely willing to prescribe Mayzent to a patient with active SPMS, and diagnosis of active SPMS is expected to increase considerably over the next two years indicating that neurologists plan to reclassify a proportion of their RRMS patients as having active SPMS in order to make them eligible for Mayzent treatment.

Along with Mayzent's ability to establish a niche in active SPMS, the other threat to Ocrevus further along the horizon may again come from Novartis, with the company's subcutaneous anti-CD20 mAb, ofatumumab. Although the agent is approximately a year away from an EMA decision, EU neurologists have high hopes for its efficacy (expected to be comparable to that of Ocrevus given its mechanistic similarities) and convenient route of administration allowing it to be administered at home. One German neurologist considers ofatumumab a "highly effective therapy concept with better controllability than [Ocrevus]."

Although optimism is high for ofatumumab's at-home administration capabilities, neurologists are accustomed to the built-in opportunities for patient monitoring that come with infusion mAbs; in reality, candidacy for ofatumumab may depend heavily on likelihood of good patient compliance and adherence. In the upcoming EU RealWorld Dynamix audit, Spherix will evaluate the impact of DMT dosing profile on brand selection during a switch. The audit will also gauge Mayzent's early performance in the active SPMS market and the brand's success in competing with current preferred DMTs for that patient segment.

About RealTime Dynamix RealTime Dynamix: Multiple Sclerosis (EU)is an independent service providing strategic guidance through rapid and comprehensive twice-yearly reports, which include market trending, launch tracking, and a fresh infusion of unique content with each wave. The 7th wave of research will publish in April 2020.

About RealWorld Dynamix RealWorld Dynamix: DMT Switching in Multiple Sclerosis (EU) is an independent, data-driven service unmasking real patient management patterns through annual reports based on chart audits of ~1,250 patients switched to a new DMT within the previous three months. The report uncovers the "why" behind treatment decisions, includes year over year trending to quantify key aspects of market evolution, and integrates specialists' attitudinal & demographic data to highlight differences between stated and actual treatment patterns. The second annual report will publish in July 2020.

About Spherix Global InsightsSpherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.

Spherix was recently recognized by Philadelphia Business Journal as a 2019 Soaring 76 recipient for the fastest growing companies in the Greater Philadelphia area and by The Philadelphia Inquirer as an Entrepreneurs' Forum 2019 Philadelphia 100 Winner for the fastest growing privately-held companies in the Greater Philadelphia area.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:Meg Stabb, Neurology Insights DirectorEmail:info@spherixglobalinsights.comwww.spherixglobalinsights.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/roches-ocrevus-continues-to-impress-in-the-eu-with-strong-uptake-in-new-start-and-switch-multiple-sclerosis-patient-segments-but-novartis-mayzent-and-ofatumumab-may-threaten-the-brands-long-term-dominance-301037781.html

SOURCE Spherix Global Insights

See original here:
Roche's Ocrevus Continues to Impress in the EU with Strong Uptake in New Start and Switch Multiple Sclerosis Patient Segments, but Novartis' Mayzent...

Neurocognitive Conditions Among People Living With HIV – Infectious Disease Advisor

Neurologic conditionsassociated with HIV remain major contributors to morbidity and mortality, and are increasingly recognizedin the aging population of individuals living with HIV who are receiving long-standingcombination antiretroviral therapy (cART).

Neurologic complications are common among individuals who are not receiving treatment for HIV as a result of immunosuppression caused by the infection, but are also widely reported after establishing a treatment regimen. Although the advent of ART, and particularly cART, have successfully reduced the risk for progression of HIV-associated neurocognitive disorders (HAND), these therapies are not effective in all patients, and thus allow for the development of neurocognitive dysfunction.2 In addition, during the early stages of infection, HIV can readily enter the central nervous system (CNS), where a persistent reservoir of HIV infection and inflammation serves to re-infect healthy cells to produce symptoms of HAND, despite therapy.1,2 And finally, drug toxicity from cART may also contribute to the development of HAND.1,2

The Evolution of HAND

The majority of patients diagnosed with HIVare on continuing ART, which is widely recognized to offer a much extended lifeexpectancy to approximately the lifespan of people without HIV; however, asmany as one-half of patients also have neurocognitive dysfunction.1,3Prior to the ART era, HIV-associated dementia, the most severe form of HAND,was common in patients with AIDS and was generally irreversible, noted Deanna Saylor, MD, MHS, director of theHopkins Global Neurology Program at Johns Hopkins University School of Medicine inBaltimore, Maryland. In the ART era, the overallprevalence of HAND is unchanged, but we have seen a dramatic shift from themost severe forms to milder forms of HAND such as asymptomatic neurocognitiveimpairment and mild neurocognitive disorder. HAND is no longer a relentlesslyprogressive disease, she said.

Further, Justin C McArthur, MBBS, MPH, director of the department of neurology at Johns Hopkins Hospital and founding director the of the Johns Hopkins/National Institute of Mental Health Research Center for Novel Therapeutics of HIV-associated Cognitive Disorders in Baltimore, Maryland, has observed that as many as 50% of the current population living with HIV is now aged >50 years, and living with the infection as a long-term condition, putting them at risk for a potentially milder form of a combination of HIV- and age-related cognitive impairment. Because of the potency of antiretrovirals and the strategies to treat everyone as early as possible, the spectrum of HIV-associated neurocognitive dysfunction has really shifted from what could be a severe disease with frank dementia and neurologic depth to a much milder type of disorder that is really analogous to [mild cognitive impairment] outside the disease spectrum,he said.

DrMcArthur coauthored a 2019 study by Dastgheyb et al4 thatdistinguished 4 phenotypes of neurocognitive dysfunction, including verbalfluency, executive function, learning and recall, and motor function. Thissmall study of 38 women helps to illuminate that HAND is not stereotypic fromone individual to another, he observed, and contains variations which may beexplainable by where the virus is in the brain or by other inherentcharacteristics of the patient, such as traumatic brain injury of acceleratedvascular disease.

HIV Reservoir in the Brain

Oneof the ongoing challenges to effective treatment of HAND is the discovery thatthe brain may serve as a reservoir for HIV replication, even when systemicviral suppression has been achieved.2,5 We know that HIV DNA can beisolated from the spinal fluid, even in individuals who are on antiretroviralsand it suggests that there is still perhaps a small but still quite importantreservoir of HIV within the central nervous system, Dr McArthur pointed out,which explains how a recurrent reseeding of infection from the brain can keepthe virus alive despite effective therapy.

Monocyte Activation

Itnow appears that a core driver for the development of HAND is cellularactivation of monocytes, macrophages, and microglia in the brain. High levelsof monocyte activation have been reported in patients with long-standing HIVmanaged by cART. The COBRA study of 134 PLHIV on cART and 79 non-HIV-infectedcontrols reported plasma markers showing high levels of monocyte activation,inflammation, and intestinal damage in the HIV cohort that were all predictiveof mortality and morbidity in treated HIV patients. At the same time, systemicT-cell activation in HIV did not have predictive value.6,7

Monocytes are cells that circulate in the blood and occasionally are found in the , but we think most of the reservoir in the brain and in the meninges are actually in tissue macrophages and in the microglia, Dr McArthur explained. These are cells that tend not to migrate. They dont move around like monocytes, they just sit there, but they can potentially induce or spread infection to other cells that are moving past them. As the mobile cells continue to travel, the infection is reintroduced into the spinal fluid, lymphatic circulation, and back into the blood, he added.

Areas for Future Research

Newavenues of research that aim to explore potential eradication of the virus byfirst eliminating the CNS reservoir are needed, Dr Saylor noted, as well as thedevelopment of treatments that fully normalize systemic and CNSinflammation.Current ART regimens reduce but do not normalize systemicand CNS inflammation, and we believe many of the non-infectious complicationsof chronic HIV infection are related to persistent low levels of inflammation,including stroke, dementia and other systemic complications, she said. Moreover,she pointed to the need for new more effective treatments to improve existingHIV-associated cognitive impairment.

DrMcArthur also highlighted that the dynamics of how the virus is produced andeliminated in specific cell types such as macrophages and microglia is quitedifferent than in the major cellular target in the body, the T-lymphocyte. Weneed to understand much more about the viral dynamics in the central nervoussystem, he said.

References

1. Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorderpathogenesis and prospects for treatment. Nat Rev Neurol. 2016;12(4):234-48.

2. D Saylor. Neurologic Complications of Human Immunodeficiency Virus Infection.

Continuum (Minneap Minn)2018;24:1397-1421.

3. Nightengale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13:1139-1151.

4. Dastgheyb RM, Sacktor N, Franklin D, et al. Cognitive Trajectory Phenotypes in Human Immunodeficiency Virus-Infected Patients.J Acquir Immune Defic Syndr. 2019;82:6170.

5. Wong ME, Jaworowski A, Hearps AC. The HIV Reservoir in Monocytes and Macrophages Front Immunol. 2019;10:1435. doi:10.3389/fimmu.2019.01435

6. Booiman T, Wit FW, Maurer I, et al. High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid. Open Forum Infect Dis. 2017;4:ofx108.

7. Wright EJ, Thakur KT, Bearden D, Birbeck GL. Global developments in HIV neurology. Handb Clin Neurol. 2018;152:265-287.

Excerpt from:
Neurocognitive Conditions Among People Living With HIV - Infectious Disease Advisor

Anatomy of a heatwave – Cosmos

By Dana M Bergstrom, Andrew Klekociuk, Diana King and Sharon Robinson

While the world rightfully focuses on the COVID-19 pandemic, the planet is still warming. This summers Antarctic weather, as elsewhere in the world, was unprecedented in the observed record.

Our research, published in Global Change Biology, describes the recent heatwave in Antarctica. Beginning in late spring east of the Antarctic Peninsula, it circumnavigated the continent over the next four months. Some of our team spent the summer in Antarctica observing these temperatures and the effect on natural systems, witnessing the heatwave first-hand.

Antarctica may be isolated from other continents by the Southern Ocean, but has worldwide impacts. It drives the global ocean conveyor belt, a constant system of deep-ocean circulation which transfers oceanic heat around the planet, and its melting ice sheet adds to global sea level rise.

Antarctica represents the simple, extreme end of conditions for life. It can be seen as a canary in the mine, demonstrating patterns of change we can expect to see elsewhere.

Most of Antarctica is ice-covered, but there are small ice-free oases, predominantly on the coast. Collectively 0.44% of the continent, these unique areas are important biodiversity hotspots for penguins and other seabirds, mosses, lichens, lakes, ponds and associated invertebrates.

This summer, Casey Research Station, in the Windmill Islands oasis, experienced its first recorded heatwave. For three days, minimum temperatures exceeded zero and daily maximums were all above 7.5C. On January 24, its highest maximum of 9.2C was recorded, almost 7C above Caseys 30-year mean for the month.

The arrival of warm, moist air during this weather event brought rain to Davis Research Station in the normally frigid, ice-free desert of the Vestfold Hills. The warm conditions triggered extensive meltwater pools and surface streams on local glaciers. These, together with melting snowbanks, contributed to high-flowing rivers and flooding lakes.

By February, most heat was concentrated in the Antarctic Peninsula at the northernmost part of the continent. A new Antarctic maximum temperature of 18.4C was recorded on February 6 at Argentinas Esperanza research station on the Peninsula - almost 1C above the previous record. Three days later this was eclipsed when 20.75C was reported at Brazils Marambio station, on Seymour Island east of the Peninsula.

The pace of warming from global climate change has been generally slower in East Antarctica compared with West Antarctica and the Antarctic Peninsula. This is in part due to the ozone hole, which has occurred in spring over Antarctica since the late 1970s.

The hole has tended to strengthen jet stream winds over the Southern Ocean promoting a generally more positive state of the Southern Annular Mode in summer. This means the Southern Oceans westerly wind belt has tended to stay close to Antarctica at that time of year creating a seasonal shield, reducing the transfer of warm air from the Earths temperate regions to Antarctica.

But during the spring of 2019 a strong warming of the stratosphere over Antarctica significantly reduced the size of the ozone hole. This helped to support a more negative state of the Southern Annular Mode and weakened the shield.

Other factors in late 2019 may have also helped to warm Antarctica. The Indian Ocean Dipole was in a strong positive state due to a late retreat of the Indian monsoon. This meant that water in the western Indian Ocean was warmer than normal. Air rising from this and other warm ocean patches in the Pacific Ocean provided energy sources that altered the path of weather systems and helped to disturb and warm the stratosphere.

Localised flooding appeared to benefit some Vestfold Hills moss banks which were previously very drought-stressed. Prior to the flood event, most mosses were grey and moribund, but one month later many moss shoots were green.

Given the generally cold conditions of Antarctica, the warmth may have benefited the flora (mosses, lichens and two vascular plants), and microbes and invertebrates, but only where liquid water formed. Areas in the Vestfold Hills away from the flooding became more drought-stressed over the summer.

High temperatures may have caused heat stress in some organisms. Antarctic mosses and lichens are often dark in colour, allowing sunlight to be absorbed to create warm microclimates. This is a great strategy when temperatures are just above freezing, but heat stress can occur once 10C is exceeded.

On King George Island, near the Antarctic Peninsula, our measurements showed that in January 2019 moss surface temperatures only exceeded 14C for 3% of the time, but in 2020 this increased fourfold (to 12% of the time).

Based on our experience from previous anomalous hot Antarctic summers, we can expect many biological impacts, positive and negative, in coming years. The most recent event highlights the connectedness of our climate systems: from the surface to the stratosphere, and from the monsoon tropics to the southernmost continent.

Under climate change, extreme events are predicted to increase in frequency and severity, and Antarctica is not immune.

Dana M Bergstrom, Principal Research Scientist, University of Wollongong; Andrew Klekociuk, Adjunct Senior Lecturer, University of Tasmania; Diana King, Research officer, University of Wollongong, and Sharon Robinson, Professor, University of Wollongong

This article is republished from The Conversation under a Creative Commons license. Read the original article.

More here:
Anatomy of a heatwave - Cosmos

Complete Anatomy App Will Use LiDAR in iPad Pro to Measure Range of Motion After Injury – MacRumors

Complete Anatomy, an iPad app from 3D4Medical, is designed to teach medical school students human anatomy with a virtual dissectible heart, real-time muscle movement mapping, nerve tracer, and microanatomy models to explore.

The feature is demoed in a YouTube video featuring Irene Walsh, the chief design officer at Complete Anatomy. According to Walsh, there has been no standardized way to measure range of motion, a problem solved with the iPad Pro's LiDAR Scanner.

Using the new 2020 iPad Pro, Complete Anatomy is able to view movements in three dimensions, using motion capture to identify which movement a person is doing. Movements are paired with 3D muscle animations, providing information on the primary muscles required to carry out the action.

Walsh says that the upcoming version of Complete Anatomy on the iPad "has the potential to transform the medical community of the future."

The LiDAR Scanner feature is coming to the Complete Anatomy app in the near future, though no specific release date is provided. So far, few apps are able to take advantage of the LiDAR Scanner, but previews like these give us an idea of just how powerful of a tool it will be when implemented by developers.

Rumors suggest that iPhones set to be released in 2020 will also include a similar 3D scanning LiDAR feature, which would allow Apple's iPhones and iPad Pro models to be used for more advanced and exciting augmented reality functions.

Read the original:
Complete Anatomy App Will Use LiDAR in iPad Pro to Measure Range of Motion After Injury - MacRumors

Anatomy of a Home-Crafted Mask: Here’s How To Make One at Home – CSRwire.com

Apr. 07 /CSRwire/ - With supplies of N95 masks at a critical low in hospitals all over the US, volunteers are helping to create new masks or extend the life of existing masks. One of our employees tells us how it works, as part of Legg Masons series on #InspireACTION.

1. Sarah, you are part of a team who sews cloth covers for N95 masks, can you tell us how the idea came about and what it is you guys are doing to help?

We heard from a friend working at a hospital in my parents hometown in Georgia how short the supply of the masks is. That inspired us to think about ways to extend the lifespan of those masks. One way is making cloth mask covers for masks which are washable and re-usable. This helps to keep the life of N95 masks clean. My mom is a big sewing bee and we can make use of a lot of fabrics in our house.

The masks are rectangular, with pleats to go over the mouth and a top and bottom tie. Originally, the ties were made from a rubber band, but after wearing this for many hours, it actually starts to rub the wearer. And, the elastic is hard to come by.A number of healthcare practitioners find it more comfortable to wear cotton ties which they can tie around their ears or head in a more comfortable way. Were focused on creating the ties to hold the mask in place.

2. How do the masks get from you to the actual hospital?

My family is part of a 3-step assembly line. We start by washing the materials and stretching it in order to make sure that once the hospitals wash the mask, they dont shrink.We sew the ties, then drive them to our friend Theresas door, leave them at her doorstep for her to then assemble the individual pieces together and drive it off to the third person in the production line. This person drives them to the hospital once they are complete.

3. With all this manual work, I am sure it takes you a long time to produce?

You dont need to have much sewing experience, its actually fairly easy and there are lots of craft shops out there who are giving away the kits. This is about speed, not precision. We use sewing machines and iron the ties afterwards to make sure they are really flat. We have produced about 60 masks in just a few days and we will be doing more. Hospital wants them to be double-sided with different fabrics, so they easily remember which side has been exposed to patients. The idea was to switch out the cloth cover between every patient but I wouldnt be surprised if they actually keep them on a bit longer.

4. Do you know how the mask are being used?

Last weeks batch went to a local hospital. The ones we are currently doing is actually for a nursing home. There are so many places like that who are in short supply. And we are also crafting Easter Cards for the senior citizens who will be in isolation over Easter. Find out more at #inspireACTION

5. If someone wanted to do this, where would they start?

Heres a helpful link:https://seekatesew.com/how-to-sew-a-face-mask-with-filter-pocket-no-elastic/

Follow this link:
Anatomy of a Home-Crafted Mask: Here's How To Make One at Home - CSRwire.com